Cognition Disorders, Oxidative Stress
Conditions
Brief summary
Objective: The aim of this study was to determine the effect of dexmedetomidine in reducing postoperative cognitive dysfunction (POCD) in cardiac surgical patients which use cardiopulmonary bypass machine (CPB). Materials and Methods: This study was double-blinded, randomized controlled trial. Patients scheduled for elective CPB facilitated cardiac surgery were randomly assigned in two groups, dexmedetomidine group (DEX) or control group. The cognitive tests (MoCA test and Short bless test) were done before the operation, 48 hours, and 7 days postoperatively. POCD was defined as a decline of 1SD of baseline score in any test. Arterial blood sample were analyzed for IL-6, IL-10, TNF-alpha and hs-CRP before induction (T0), after separation from CPB (T1), arrival at ICU (T2) and 24-hour after surgery (T3). Primary outcome was the incidence of POCD and the secondary outcomes were inflammatory response, other postoperative complications, ICU and hospital stay.
Detailed description
After the patients were enrolled in the study, they were allocated into Dexmedetomidine group or control group by computer-based randomization. Patients, surgeons, anesthesiologists and researchers who performed the cognitive test were all blinded to the study groups. General anesthesia was induced with intravenously midazolam 0.1-0.2 mg/kg and fentanyl 5-10 mcg/kg or Thiopental 3-5 mg/kg or Propofol 2 mg/kg. Patients were intubated with pancuronium 1 mg/kg or rocuronium 0.6-1 mg/kg. Anesthesia was maintained with nitrous oxide in oxygen, isoflurane, fentanyl, and pancuronium or rocuronium as required. Standard monitoring was provided including an indwelling radial artery catheter and central venous catheter. Bispectral index (BIS) monitoring was applied and maintained between 40-60 through the operation. Cerebral oximetry was monitored both sides of the brain by non-invasive oximeters at forehead area and the data were recorded. After skin incision, the Dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.The control group received a loading dose and continuous IV infusion of normal saline at the same rate. During the cardiopulmonary bypass, mean arterial pressure was maintained at 60-80 mmHg or 20% from baseline. If hypertension was detected, Nicardipine 0.2 mg was given intravenously. Ephedrine 6 mg or norepinephrine 4 mcg were given within 5 minutes and repeated every 5 minutes if hypotension was presented. Atropine 0.6 mg was administered for bradycardia (heart rate less than 50 beats per minute). After the operation, patients were transferred to Cardio-thoracic intensive care unit and received standard postoperative cardiac surgery care. 2 neuropsychological tests were used to evaluate patients' cognitive function; Montreal Cognitive Assessment (MoCA) and Short blessed test (SBT). These tests were chosen by King Chulalongkorn Memorial Hospital's psychiatrist based on previous studies and the statement consensus on assessment of neurobehavioral outcomes after cardiac surgery published in 1995. All patients were evaluated their cognitive function for 3 points of time, 1st time was at preoperative period (T1), 2nd time was at 48 hours postoperatively (T2) and the last one was at 7 days postoperatively or the day at discharge from the hospital (T3). POCD was defined as a decline of 1 standard deviation (1SD) of baseline score in any test. Blood samples were taken through the radial artery catheter, and sampling times were chosen as follows: before the induction of anaesthesia (T0); after separated from CPB (T1); arrival at intensive care unit (ICU) (T2); 24 hr after surgery (T3). Plasma Tissue Necrotic Factor-Alpha (TNF-α), Interleukin-6 (IL-6) and Interleukin-10 (IL-10) levels were measured by Magnetic Luminex Performance Assay. High sensitivity C-reactive protein (CRP) level were also measured by nephelometry.
Interventions
After skin incision, the dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
The control group received a loading dose and continuous IV infusion of normal saline at the same volume and rate as in the dexmedetomidine group
Sponsors
Study design
Eligibility
Inclusion criteria
* American Society of Anesthesiologists (ASA) physical status I-III.
Exclusion criteria
* patients who were allergy to medication in the research regimen * preoperative left ventricular ejection fraction less than 30% * body mass index more than 35 kg/m2 * preoperative mean arterial pressure less than 60 mmHg * preoperative heart rate less than 45/min * patients with impaired renal function (serum creatinine more than 1.5 mg/dl in female and 2 mg/dl in male) * active liver disease, and who had history of symptomatic cerebrovascular disease * psychiatric problem and other neurological diseases * patients who cannot read
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Numbers of Participants With Postoperative Cognitive Dysfunction (POCD) | 48 hours | POCD was defined as a decline of 1 standard-deviation (1SD) of baseline score in either MoCA test or short bless test. |
| Number of Participants With Postoperative Cognitive Dysfunction (POCD) | 7 days | POCD was defined as a decline of 1SD of baseline score in either MoCA test or short bless test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Postoperative Complications | 7 days | Neurological complication, Delirium, dysrhythmia, death |
| Hospital Stay in Days | 30 days | — |
| ICU Stay in Hours | 7 days | — |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dex Group After skin incision, the Dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation. | 49 |
| Placebo Group The control group received a loading dose and continuous IV infusion of normal saline at the same rate. | 50 |
| Total | 99 |
Baseline characteristics
| Characteristic | Placebo Group | Dex Group | Total |
|---|---|---|---|
| Age, Continuous | 52.72 years STANDARD_DEVIATION 10.975 | 51.43 years STANDARD_DEVIATION 13.077 | 52.08 years STANDARD_DEVIATION 12.017 |
| Aortic Cross-clamp Time | 99.88 minutes STANDARD_DEVIATION 38.38 | 92.69 minutes STANDARD_DEVIATION 34.03 | 96.32 minutes STANDARD_DEVIATION 36.287 |
| Atrial fibrillation | 13 Participants | 12 Participants | 25 Participants |
| Baseline Montreal Cognitive Assessment scores (0-30 points) | 22.88 points STANDARD_DEVIATION 3.707 | 22.84 points STANDARD_DEVIATION 4.464 | 22.86 points STANDARD_DEVIATION 4.078 |
| Baseline Short Blessed Test score (0-28 points) | 5.30 points STANDARD_DEVIATION 5.754 | 4.98 points STANDARD_DEVIATION 4.922 | 5.14 points STANDARD_DEVIATION 5.334 |
| BMI | 26.19 Kilograms per metre square STANDARD_DEVIATION 19.21 | 23.08 Kilograms per metre square STANDARD_DEVIATION 3.09 | 24.65 Kilograms per metre square STANDARD_DEVIATION 13.8424 |
| Cardiopulmonary Bypass Time | 132.34 minutes STANDARD_DEVIATION 46.55 | 120.59 minutes STANDARD_DEVIATION 41.52 | 126.53 minutes STANDARD_DEVIATION 44.299 |
| Diabetes Mellitus | 10 Participants | 6 Participants | 16 Participants |
| Hypertension | 28 Participants | 22 Participants | 50 Participants |
| Left Ventricular Ejection Fraction | 63.27 percentage of left ventricular ejection STANDARD_DEVIATION 11.55 | 62.26 percentage of left ventricular ejection STANDARD_DEVIATION 11.53 | 62.7717 percentage of left ventricular ejection STANDARD_DEVIATION 11.48959 |
| Operation type CABG | 18 Participants | 13 Participants | 31 Participants |
| Operation type CABG with valve surgery | 1 Participants | 5 Participants | 6 Participants |
| Operation type Multiple valve surgery | 12 Participants | 6 Participants | 18 Participants |
| Operation type Single valve surgery | 19 Participants | 25 Participants | 44 Participants |
| Operative Time | 309.28 minutes STANDARD_DEVIATION 79.97 | 301.73 minutes STANDARD_DEVIATION 87.7 | 305.55 minutes STANDARD_DEVIATION 83.541 |
| Region of Enrollment Thailand | 50 Participants | 49 Participants | 99 Participants |
| Serum Creatinine | 0.95 miligram per decilitre STANDARD_DEVIATION 0.27 | 0.94 miligram per decilitre STANDARD_DEVIATION 0.24 | 0.9445 miligram per decilitre STANDARD_DEVIATION 0.25329 |
| Sex: Female, Male Female | 18 Participants | 23 Participants | 41 Participants |
| Sex: Female, Male Male | 32 Participants | 26 Participants | 58 Participants |
| Weight | 62.69 kilograms STANDARD_DEVIATION 11.81 | 60.88 kilograms STANDARD_DEVIATION 12.5 | 61.794 kilograms STANDARD_DEVIATION 12.128 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 49 | 0 / 50 |
| other Total, other adverse events | 13 / 49 | 11 / 50 |
| serious Total, serious adverse events | 0 / 49 | 1 / 50 |
Outcome results
Number of Participants With Postoperative Cognitive Dysfunction (POCD)
POCD was defined as a decline of 1SD of baseline score in either MoCA test or short bless test.
Time frame: 7 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dex Group | Number of Participants With Postoperative Cognitive Dysfunction (POCD) | 7 Participants |
| Placebo Group | Number of Participants With Postoperative Cognitive Dysfunction (POCD) | 6 Participants |
Numbers of Participants With Postoperative Cognitive Dysfunction (POCD)
POCD was defined as a decline of 1 standard-deviation (1SD) of baseline score in either MoCA test or short bless test.
Time frame: 48 hours
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dex Group | Numbers of Participants With Postoperative Cognitive Dysfunction (POCD) | 12 Participants |
| Placebo Group | Numbers of Participants With Postoperative Cognitive Dysfunction (POCD) | 8 Participants |
Hospital Stay in Days
Time frame: 30 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dex Group | Hospital Stay in Days | 9.367 days | Standard Deviation 3.604 |
| Placebo Group | Hospital Stay in Days | 10.42 days | Standard Deviation 4.248 |
ICU Stay in Hours
Time frame: 7 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dex Group | ICU Stay in Hours | 33.79 hours | Standard Deviation 36.43 |
| Placebo Group | ICU Stay in Hours | 38.44 hours | Standard Deviation 39.17 |
Number of Participants With Postoperative Complications
Neurological complication, Delirium, dysrhythmia, death
Time frame: 7 days
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Dex Group | Number of Participants With Postoperative Complications | Postoperative delirium | 0 Participants |
| Dex Group | Number of Participants With Postoperative Complications | Embolic Stroke | 0 Participants |
| Placebo Group | Number of Participants With Postoperative Complications | Postoperative delirium | 1 Participants |
| Placebo Group | Number of Participants With Postoperative Complications | Embolic Stroke | 1 Participants |